A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
Clinical trial NCT05259839 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05259839
- Sponsor
- AbbVie
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-10-20
- Primary completion
- 2033-09-01
- Enrollment
- 283
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.